Drug Search Results
More Filters [+]

IMF-001

Alternative Names: imf-001, imf001, imf 001
Latest Update: 2015-03-10
Latest Update Note: Clinical Trial Update

Product Description

a vaccine, to patients with solid tumors that express NY-ESO-1 antigen; IMF-001 is a CHP-NY-ESO-1 complex consisting of recombinant NY-ESO-1 protein and cholesteryl hydrophobized pullulan (CHP). CHP forms colloidally stable nanoparticles in water and complexes with substrate such as NY-ESO-1 protein. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01234012)

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: ImmunoFrontier
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for IMF-001

Countries in Clinic: Japan

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Esophageal Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

JapicCTI-101088

P1

Active

Esophageal Cancer

2011-06-30

Recent News Events

Date

Type

Title